LDLR and familial hyperaldosteronism: Our findings support the view that in patients with FH, even in those with HoFH whose LDL receptors are defective, PCSK9 inhibitors used in combination with statins could reduce LDL‐C levels further and may be of added benefit in the treatment of these high‐risk patients.